Mirati Therapeutics Inc Stock Research

Market Summary

USD38.40-5.44

Market Closed

-12.41%

MRTX Stock Price

MRTX RSI Chart

MRTX Valuation

Market Cap

2.2B

Price/Earnings (Trailing)

-3.03

Price/Sales (Trailing)

118.18

EV/EBITDA

-2.7

Price/Free Cashflow

-3.7

MRTX Price/Sales (Trailing)

MRTX Profitability

EBT Margin

-5953.35%

Return on Equity

-74.35%

Return on Assets

-61.6%

Free Cashflow Yield

-27.06%

MRTX Fundamentals

MRTX Revenue

Revenue (TTM)

18.9M

Revenue Y/Y

-73.94%

Revenue Q/Q

667.34%

MRTX Earnings

Earnings (TTM)

-737.1M

Earnings Y/Y

2.02%

Earnings Q/Q

8.84%

Price Action

52 Week Range

32.96101.30

(Low)(High)

Last 7 days

-5.7%

Last 30 days

1.2%

Last 90 days

-4.6%

Trailing 12 Months

-25.4%

MRTX Financial Health

Current Ratio

6.96

MRTX Investor Care

Shares Dilution (1Y)

4.75%

Diluted EPS (TTM)

-12.97

Peers (Alternatives to Mirati Therapeutics)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
BGNE	310.3B	1.6B	-8.12%	92.29%	-161.87	199.29	77.54%	1.62%
ABBV	285.4B	56.7B	-13.97%	-3.48%	24.12	4.92	0.03%	-39.22%
REGN	87.6B	12.4B	-7.48%	7.49%	20.2	7.2	-25.07%	-47.28%
VRTX	85.7B	9.2B	0.30%	24.35%	26.28	9.3	15.86%	32.99%
ALNY	23.1B	1.0B	-9.21%	46.34%	-21.7	22.28	22.88%	-19.27%
SRPT	12.0B	975.7M	3.69%	90.82%	-10.76	12.3	27.41%	-212.78%
UTHR	9.9B	2.0B	-6.22%	-2.22%	13.62	5	12.05%	52.86%
MID-CAP
MDGL	5.1B	504.0K	-4.45%	362.54%	-16.36	2.5K	-66.53%	-27.52%
RARE	3.5B	363.3M	14.61%	9.13%	-4.95	9.64	3.39%	-55.81%
BPMC	3.3B	204.6M	20.71%	4.83%	-5.64	16.03	-7.52%	10.65%
MRTX	2.2B	18.9M	1.15%	-25.44%	-3.03	118.18	-	-16.17%
SMALL-CAP
CYTK	3.6B	-	-0.47%	-0.26%	-8.26	37.64	34.30%	-67.22%
CPRX	1.2B	256.5M	-28.87%	71.03%	12.35	4.79	66.85%	120.61%
MGNX	318.5M	165.3M	-20.15%	43.43%	-3.49	1.93	130.70%	57.97%
CRBP	43.9M	881.7K	8.16%	3439.25%	-0.87	19.11	-77.61%	-29.84%

Financials for Mirati Therapeutics

Income Statement (Last 12 Months)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Revenue	51.9%	18,894,000	12,436,000
Operating Expenses	2.1%	788,088,000	772,025,000	756,742,000	716,160,000	697,779,000
S&GA Expenses	8.1%	259,337,000	239,798,000	212,512,000	186,897,000	162,280,000
R&D Expenses	-0.8%	527,334,000	531,627,000	544,230,000	529,263,000	535,499,000
EBITDA	0.8%	-737,430,000	-743,254,000	-576,350,000	-	-
EBITDA Margin	-	-59.30	-	-	-	-
Earnings Before Taxes	0.7%	-740,359,000	-745,854,000	-	-	-
EBT Margin	-	-59.53	-	-	-	-
Net Income	0.5%	-737,067,000	-740,867,000	-738,012,000	-644,505,000	-634,490,000
Net Income Margin	-	-59.57	-	-	-	-
Free Cahsflow	1.9%	-575,421,000	-586,445,000	-496,437,000	-448,681,000	-

Balance Sheet					(In Millions)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Assets	-14.0%	1,034	1,203	1,303	1,280	1,421
Current Assets	-15.3%	939	1,109	1,226	1,203	1,343
Cash Equivalents	3.1%	243	235	299	266	305
Inventory	27.5%	4.00	3.00	-	-	-
Net PPE	-2.0%	17.00	18.00	18.00	17.00	17.00
Liabilities	-17.0%	171	206	174	168	172
Current Liabilities	-21.9%	125	159	127	119	124
Shareholder's Equity	-13.4%	863	997	1,129	1,112	1,249
Retained Earnings	-7.5%	-2,637	-2,452	-2,250	-2,076	-1,900
Additional Paid-In Capital	1.4%	3,502	3,453	3,386	3,185	3,145
Shares Outstanding	0.5%	58.00	58.00	58.00	56.00	56.00

Cashflow (Last 12 Months)					(In Thousands)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Cashflow From Operations	-5.2%	-600,283	-570,570	-579,755	-488,978	-438,853
Share Based Compensation	2.2%	190,244	186,188	158,459	142,400	131,685
Cashflow From Investing	64.5%	371,399	225,803	-4,332	-17,573	-83,818
Cashflow From Financing	-0.5%	166,144	166,944	640,306	491,433	497,864

Risks for MRTX

What is the probability of a big loss on MRTX?

99.2%

Probability that Mirati Therapeutics stock will be more than 20% underwater in next one year

88.1%

Probability that Mirati Therapeutics stock will be more than 30% underwater in next one year.

68.5%

Probability that Mirati Therapeutics stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does MRTX drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Mirati Therapeutics was unfortunately bought at previous high price.

Drawdowns

Returns for MRTX

Cumulative Returns on MRTX

75.6%

10-Year Cumulative Returns

13.7%

7-Year Cumulative Returns

-0.2%

5-Year Cumulative Returns

-24.4%

3-Year Cumulative Returns

What are the long-term rolling returns for MRTX?

FIve years rolling returns for Mirati Therapeutics.

Annualized Returns

Which funds bought or sold MRTX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-05-22	AMERIPRISE FINANCIAL INC	sold off	-100	-28,869,000	-	-%
2023-05-18	NEW YORK STATE COMMON RETIREMENT FUND	added	0.36	-1,850,000	8,634,000	0.01%
2023-05-18	INTERNATIONAL BIOTECHNOLOGY TRUST PLC	unchanged	-	-1,983,720	9,071,920	2.53%
2023-05-18	JPMORGAN CHASE & CO	added	39.16	276,000	2,225,000	-%
2023-05-17	Thrivent Financial for Lutherans	reduced	-46.3	-3,379,000	2,662,000	0.01%
2023-05-17	VIRGINIA RETIREMENT SYSTEMS ET AL	sold off	-100	-474,912	-	-%
2023-05-16	JANE STREET GROUP, LLC	reduced	-21.6	-3,074,290	5,544,580	-%
2023-05-16	SUSQUEHANNA INTERNATIONAL GROUP, LLP	added	435	10,414,800	13,481,900	-%
2023-05-16	Utah Retirement Systems	sold off	-100	-348,887	-	-%
2023-05-16	Castleview Partners, LLC	sold off	-100	-226	-	-%

Latest Funds Activity

Are funds buying MRTX calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own MRTX

No. of Funds

Mirati Therapeutics News

Schedule 13G FIlings of Mirati Therapeutics

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2023	armistice capital, llc	6.06%	3,488,000	SC 13G
Feb 14, 2023	avoro capital advisors llc	9.6%	5,555,555	SC 13G/A
Feb 14, 2023	rtw investments, lp	6.3%	3,643,114	SC 13G
Feb 14, 2023	perceptive advisors llc	3.8%	2,191,425	SC 13G/A
Feb 09, 2023	vanguard group inc	8.64%	4,973,888	SC 13G/A
Feb 06, 2023	wellington management group llp	5.24%	3,016,335	SC 13G/A
Feb 15, 2022	perceptive advisors llc	5.9%	3,283,783	SC 13G/A
Feb 11, 2022	avoro capital advisors llc	9.2%	5,075,000	SC 13G/A
Feb 09, 2022	fmr llc	-	0	SC 13G/A
Feb 04, 2022	wellington management group llp	5.70%	3,145,632	SC 13G

MRTX Fair Value

Recent SEC filings of Mirati Therapeutics

View All Filings

Date Filed	Form Type	Document
May 24, 2023	8-K	Current Report
May 24, 2023	4	Insider Trading
May 12, 2023	S-8	Employee Benefits Plan
May 12, 2023	8-K	Current Report
May 09, 2023	8-K	Current Report
May 09, 2023	10-Q	Quarterly Report
Apr 06, 2023	DEF 14A	DEF 14A
Apr 05, 2023	ARS	ARS
Feb 28, 2023	8-K	Current Report
Feb 28, 2023	10-K	Annual Report

Latest Insider Trading transactions for MRTX

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-05-24	Christensen Jamie	sold	-28,034	45.2905	-619	evp & chief scientific officer
2023-01-20	FUCHS HENRY J	acquired	-	-	4,444	-
2023-01-20	Johnson Craig A	acquired	-	-	4,444	-
2023-01-20	Meek David D.	acquired	-	-	89,379	chief executive officer
2023-01-20	Christensen Jamie	acquired	-	-	26,864	evp, chief scientific officer
2023-01-20	Cherrington Julie M	acquired	-	-	4,444	-
2023-01-20	Stelzer Laurie	acquired	-	-	26,864	cfo
2023-01-20	Sharp Shalini	acquired	-	-	4,444	-
2023-01-20	Hickey Benjamin	acquired	-	-	36,394	evp, chief commercial officer
2023-01-20	Hasnain Faheem	acquired	-	-	6,333	-

About Mirati Therapeutics

David D. Meek

www.mirati.com

420

Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.

MRTX Income Statement

2023-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Total revenue	$ 7,167	$ 709
Revenue
Total revenue	7,167	709
Operating expenses
Cost of product revenue	558	0
Cost of product revenue - intangible asset amortization	259	0
Research and development	126,683	130,976
Selling, general and administrative	73,490	53,951
Total operating expenses	200,990	184,927
Loss from operations	(193,823)	(184,218)
Other income (expense), net	9,237	(4,168)
Net loss	(184,586)	(188,386)
Foreign currency translation adjustment	(31)	0
Unrealized gain (loss) on available-for-sale investments	2,043	(4,802)
Comprehensive loss	$ (182,574)	$ (193,188)
Basic net loss per share (USD per share)	$ (3.18)	$ (3.40)
Diluted net loss per share (USD per share)	$ (3.18)	$ (3.40)
Weighted average common shares outstanding, basic (shares)	58,031,642	55,468,851
Weighted average common shares outstanding, diluted (shares)	58,031,642	55,468,851
Product Revenue
Total revenue	$ 6,291	$ 0
Revenue
Total revenue	6,291	0
License and Collaboration Revenue
Total revenue	876	709
Revenue
Total revenue	$ 876	$ 709

MRTX Balance Sheet

2023-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 241,925	$ 235,260
Short-term investments	660,369	848,577
Accounts receivable, net	6,227	865
Inventory	3,849	3,020
Other current assets	26,980	21,239
Total current assets	939,350	1,108,961
Property and equipment, net	17,185	17,540
Intangible asset, net	14,655	14,914
Long-term investment	3,353	3,465
Right-of-use asset	35,783	36,122
Other long-term assets	23,435	21,645
Total assets	1,033,761	1,202,647
Current liabilities
Accounts payable	22,320	38,861
Accrued liabilities	102,280	120,587
Total current liabilities	124,600	159,448
Lease liability	43,227	43,661
Other liabilities	3,304	3,022
Total liabilities	171,131	206,131
Commitments and contingencies (see Note 11)
Shareholders' equity
Preferred stock, $0.001 par value, 10,000,000 shares authorized; none issued and outstanding at both March 31, 2023 and December 31, 2022	0	0
Common stock, $0.001 par value; 100,000,000 authorized; 58,148,416 and 57,854,559 issued and outstanding at March 31, 2023 and December 31, 2022, respectively	58	58
Additional paid-in capital	3,501,754	3,453,066
Accumulated other comprehensive loss	(1,707)	(3,719)
Accumulated deficit	(2,637,475)	(2,452,889)
Total shareholders' equity	862,630	996,516
Total liabilities and shareholders' equity	$ 1,033,761	$ 1,202,647